HC Wainwright & Co. Maintains Buy on Legend Biotech, Raises Price Target to $85
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Mitchell Kapoor maintains a 'Buy' rating on Legend Biotech (NASDAQ:LEGN) and raises the price target from $82 to $85.
July 21, 2023 | 10:12 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The 'Buy' rating maintained by HC Wainwright & Co. and the increase in price target from $82 to $85 could potentially boost investor confidence in Legend Biotech.
Analyst ratings and price targets can significantly influence investor sentiment. The maintained 'Buy' rating and increased price target indicate a positive outlook for Legend Biotech, which could lead to increased demand for the stock and potentially drive its price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100